|
【结 构 式】 
|
【分子编号】37342 【品名】(2S)-2-[[((2S)-1-[(2S,3S)-2-[([(2S)-1-[(2S)-2-[((2S)-2-[[(2S)-2-[(5-aminopentanoyl)amino]-4-(cyclohexyloxy)-4-oxobutanoyl]amino]-3-phenylpropanoyl)amino]-5-(benzyloxy)-5-oxopentanoyl]pyrrolidinyl]carbonyl)amino]-3-methylpentanoyl]pyrrolidinyl)carbonyl]amino]-4-methylpentanoic acid 【CA登记号】 |
【 分 子 式 】C58H84N8O13 【 分 子 量 】1101.35108 【元素组成】C 63.25% H 7.69% N 10.17% O 18.89% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(XXI)Then, two sequential couplings with N-Boc-5-aminopentanoic acid (XX), followed by deprotections with trifluoroacetic acid in the presence of ethyl methyl sulfide, provided peptide resins (XXI) and (XXII).
| 【1】 DiMaio, J. (National Research Council of Canada); Thrombin inhibitors based on the amino acid sequence of hirudin. JP 1999502203; WO 9629347 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XIX) | 37340 | (2S)-2-[[((2S)-1-[(2S,3S)-2-[([(2S)-1-[(2S)-2-[((2S)-2-[[(2S)-2-amino-4-(cyclohexyloxy)-4-oxobutanoyl]amino]-3-phenylpropanoyl)amino]-5-(benzyloxy)-5-oxopentanoyl]pyrrolidinyl]carbonyl)amino]-3-methylpentanoyl]pyrrolidinyl)carbonyl]amino]-4-methylpentanoic acid | C53H75N7O12 | 详情 | 详情 | |
| (XX) | 37341 | 5-[(tert-butoxycarbonyl)amino]pentanoic acid | C10H19NO4 | 详情 | 详情 | |
| (XXI) | 37342 | (2S)-2-[[((2S)-1-[(2S,3S)-2-[([(2S)-1-[(2S)-2-[((2S)-2-[[(2S)-2-[(5-aminopentanoyl)amino]-4-(cyclohexyloxy)-4-oxobutanoyl]amino]-3-phenylpropanoyl)amino]-5-(benzyloxy)-5-oxopentanoyl]pyrrolidinyl]carbonyl)amino]-3-methylpentanoyl]pyrrolidinyl)carbonyl]amino]-4-methylpentanoic acid | C58H84N8O13 | 详情 | 详情 | |
| (XXII) | 37343 | (2S)-2-([[(2S)-1-((2S,3S)-2-[[((2S)-1-[(2S,5S,8S)-20-amino-5-benzyl-2-[3-(benzyloxy)-3-oxopropyl]-8-[2-(cyclohexyloxy)-2-oxoethyl]-4,7,10,16-tetraoxo-3,6,9,15-tetraazaicos-1-anoyl]pyrrolidinyl)carbonyl]amino]-3-methylpentanoyl)pyrrolidinyl]carbonyl]amino)-4-methylpentanoic acid | C63H93N9O14 | 详情 | 详情 |
Extended Information